Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Single-Dose Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib

Trial Profile

A Phase 1, Open-Label, Single-Dose Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2018

At a glance

  • Drugs Erdafitinib (Primary)
  • Indications Breast cancer; Cholangiocarcinoma; Gastric cancer; Liver cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Urogenital cancer
  • Focus Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 06 Dec 2018 Planned initiation date changed from 12 Nov 2018 to 6 Dec 2018.
    • 09 Nov 2018 Planned initiation date changed from 31 Oct 2018 to 12 Nov 2018.
    • 05 Sep 2018 Planned initiation date changed from 9 Jul 2018 to 31 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top